Terug

Nippon Shinyaku Co., Ltd.

Datakwaliteit: 100%

NPPNY

OTC Healthcare Drug Manufacturers - Specialty & Generic

€ 8,07

▼ € 0,39 (-4,56%)

Marktkapitalisatie: 2,17B

Ook genoteerd als NPNKF OTC

Dagbereik

€ 8,07 € 8,71

52-Weeksbereik

€ 5,03 € 15,21

Volume

50D / 200D Gem.

€ 8,65 / € 6,75

Vorige Slotkoers

€ 8,45

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek	Aandeel	Sector Mediaan
P/E	0,1	0,4
P/B	0,0	2,9
ROE %	13,9	3,8
Net Margin %	20,3	3,9
Rev Growth 5Y %	7,1	10,0
D/E	0,0	0,2

Belangrijkste Punten

Revenue grew 7,08% annually over 5 years — modest growth

Earnings grew 25,94% over the past year

ROE of 13,94% — decent returns on equity

Net margin of 20,32% shows strong profitability

Debt/Equity of 0,01 — conservative balance sheet

Generating 32,77B in free cash flow

Groei

Revenue Growth (5Y)

7,08%

Revenue (1Y)8,08%

Earnings (1Y)25,94%

FCF Growth (3Y)50,64%

Kwaliteit

Return on Equity

13,94%

ROIC11,04%

Net Margin20,32%

Op. Margin22,94%

Veiligheid

Debt / Equity

0,01

Current Ratio4,94

Interest Coverage253,54

Waardering

P/E Ratio

0,07

P/B Ratio0,01

EV/EBITDA-1,37

Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	8,08%	Revenue Growth (3Y)	5,42%
Earnings Growth (1Y)	25,94%	Earnings Growth (3Y)	19,47%
Revenue Growth (5Y)	7,08%	Earnings Growth (5Y)	13,61%
Profitability
Revenue (TTM)	160,23B	Net Income (TTM)	32,56B
ROE	13,94%	ROA	11,48%
Gross Margin	68,10%	Operating Margin	22,94%
Net Margin	20,32%	Free Cash Flow (TTM)	32,77B
ROIC	11,04%	FCF Growth (3Y)	50,64%
Safety
Debt / Equity	0,01	Current Ratio	4,94
Interest Coverage	253,54	Dividend Yield	0,03%
Valuation
P/E Ratio	0,07	P/B Ratio	0,01
P/S Ratio	0,01	PEG Ratio	0,30
EV/EBITDA	-1,37	Dividend Yield	0,03%
Market Cap	2,17B	Enterprise Value	-50,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	160,23B	148,26B	144,18B	137,48B	121,89B
Net Income	32,56B	25,85B	22,81B	24,99B	19,54B
EPS (Diluted)	120,82	95,96	84,68	92,74	72,53
Gross Profit	109,12B	97,02B	88,20B	87,29B	71,93B
Operating Income	36,76B	31,39B	30,05B	32,95B	26,13B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	283,64B	263,40B	237,45B	219,94B	197,03B
Total Liabilities	36,30B	42,87B	41,52B	39,06B	34,49B
Shareholders' Equity	247,03B	220,22B	195,62B	180,58B	162,25B
Total Debt	2,72B	2,87B	2,66B	2,71B	2,84B
Cash & Equivalents	55,24B	58,09B	60,05B	60,57B	47,77B
Current Assets	149,74B	164,29B	157,87B	149,72B	139,09B
Current Liabilities	30,32B	37,34B	35,18B	32,03B	31,51B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#493 of 1024

Custom Deep Value Investing (Seth Klarman)

#533 of 820

Value Defensive Investing (Benjamin Graham)

#668 of 708

Recente Activiteit

Ingestapt Cash Flow Compounder

Mar 24, 2026

Ingestapt Deep Value Investing (Seth Klarman)

Mar 24, 2026

Ingestapt Defensive Investing (Benjamin Graham)

Mar 24, 2026